9/12 5:30 pm - 8:30 pm
HBA presents 'Putting Academia-Industry Research Partnerships to Work.' Novartis, 1 Health Plaza, East Hanover, NJ more
9/24 4:00 pm - 6:00 pm
CURE presents healthcare investment banker Anthony Gibney of Leerink Swann. Yale Anlyan Center, 300 Cedar Street, New Haven more
10/1 4:00 pm - 6:00 pm
CURE/Yale BioHaven presents Trevi Therapeutics. Anlyan Center, 300 Cedar Street, New Haven. Watch for details.
10/8-9 12th annual BIO Investor Forum. The Palace Hotel, San Francisco more
10/15 6:00 pm - 9:30 pm
HBA presents Women's Healthcare Innovation and Leadership Showcase. Sanofi Campus, 55 Corporate Drive Auditorium, Bridgewater, NJ more
11/7 10:00 am - 3:00 pm
CT Innovation Summit. Mentor meetings, awards ceremony, and more. Co-sponsored by CURE. Oakdale Theater, Wallingford more
11/11-13 The BIO Convention in China. National Convention Center, Beijing more
12/3 5:45 pm - 7:30 pm
CURE Holiday Party. 'The best networking in town.' Café George, 300 George Street, New Haven. Save the Date!

Cost-saving discounts for CURE members!
CURE members can now receive discounts on various products and services, such as lab supplies, shipping services, and gases more

Boehringer Ingelheim Pharmaceuticals
900 Ridgebury Road
Ridgefield, CT 06877

Phone: 203-798-9988
Fax: 203-791-6442
Website: http://www.boehringer-ingelheim.com

Amy Fry, Vice President Communications and Public Relations

General Information
Boehringer Ingelheim Group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 144 affiliates in 34 countries and nearly 36,000 employees. Since it was founded in 1885, the family-owned company as been committed to researching, developing, manufacturing an and marketing novel products of high therapeutic value for human and veterinary medicine. In 2004, Boehringer Ingelheim posted net sales of US $10.2 billion (8.2 billion euro) while spending nearly one fifth of net sales in its largest business segment, Prescription Medicines, on research and development.

Research Activities
Chronic obstructive pulmonary disease, chronic inflammatory diseases, antivirals, neurological diseases and stroke.

ALUPENT (metaproterenol sulfate) for bronchial asthma and for reversible bronchospasm associated with bronchitis and emphysema, ATROVENT (ipratropium bromide) and COMBIVENT (ipratropium bromide/albuterol sulfate) for maintenance therapy of brochospasm associated with chronic obstructive pulmonary disease; MICARDIS (telmisartan), CATAPRES (clonidine) and CATAPRES-TTS (clonidine hydrochloride) for treating high blood pressure; FLOMAX (tamsulosin) for treatment of the signs and symptoms of benign prostate hyperplasia (licensed from Yamanouchi Pharmaceuticals, Inc.); MIRAPEX (pramipexole) for the signs and symptoms of idiopathic Parkinson's disease, PERSANTINE (dipyridamole) and MEXITIL (mexiletine hydrochloride) for managing cardiovascular disease; and VIRAMUNE (nevirpaine for managing HIV infection (marketed by Boehringer Ingelheim affilate Roxane Laboratories, Inc.).

Other Information
Ownership: Private
Parent Company: Boehringer Ingelheim Corporation
CT Employees: 1,900
Total Sales Revenue: $4.97 Million '98
Annual Budget: $902 Million '98